-PTI Drug regulator DGCI is conducting a "focussed scrutiny" of medicines sold by Ranbaxy and some other drug makers, but says it remains confident of the quality standards of Indian medicines despite concerns raised by US authorities over some of Ranbaxy's products. While the company continues to assert that its drugs meet all regulatory standards, a few hospitals and pharmacies have adopted a cautious stand on use of its products. However, a majority...

-The Telegraph The Supreme Court today refrained from passing any order on a plea for early listing of a PIL that had sought closure of pharmaceutical giant Ranbaxy, recently penalised by US authorities for allegedly supplying adulterated and substandard drugs. The public interest petition sought registration of criminal cases under the penal code and also the Drugs and Cosmetics Act, 1947, against company officials for allegedly cheating millions of patients in the...

-The Business Standard The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals. Last week, Ranbaxy had agreed to...

-The Hindustan Times The Maharashtra chapter of the central government's flagship Integrated Child Development Scheme (ICDS) has criticised the state government for lack of transparency in the contract allocation process, saying it was done to favour the same vested parties.   The principal adviser of the office of commissioner Biraj Patnaik, who drafted the reports, expressed the need for the institution of a Special Investigation Team to investigate the matter. Hindustan Times, on Saturday,...

Regulations covering public health should override personal rights and the country cannot wait any more for a good public health law. The health care industry, including institutions of medical education, hospitals and pharmaceutical businesses, have grown into behemoths that can do considerable harm in the absence of independent and effective regulatory systems. While there are no success stories in the regulation of any kind of industry in India, I will focus...